Dyadic International is a global biotechnology company focused on improving and applying its proprietary C1 gene expression platform, a patented genetically modified strain of the fungus Myceliophthora thermophila, to address opportunities in human and animal health markets. The C1 platform can help bring biologic drugs to market faster, in greater volumes, and at lower cost than existing platforms like CHO cells. Dyadic pursues R&D collaborations and licensing arrangements to develop and manufacture biopharmaceuticals using the C1 platform.